|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Hansen Medical (Nasdaq:HNSN ), a developer of products using robotics for controlling catheters and catheter-based technologies. |
|---|---|
| Transferring Party | AorTx, Inc, an early stage developer of “percutaneous” or catheter-based valve technology. |
| Sector | Medical Devices |
| Date | November 20, 2007 |
| Analysis Leverages Hanson's Sensei™ Robotic Catheter system, which is currently marketed for electrophysiology procedures, into the rapidly developing market for percutaneous heart valve therapy. With only $6m in sales and a market cap of more than $600m, Hansen seeks to augment its core technology. Deal value -- $4.2m in stock, $4.5m cash, and cancellation of $1m of AorTx liabilities. Also milestones payment of $15m in stock and another $15m in cash upon achieving certain regulatory clearances and performance levels. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2010 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |